Usana Health Sciences (USNA) EBITDA (2010 - 2026)

Usana Health Sciences (USNA) has 17 years of EBITDA data on file, last reported at $8.7 million in Q2 2026.

• EBITDA for Q2 2026 came in at $8.7 million, down 5.51% year-over-year; the trailing twelve-month figure through Apr 2026 was $16.0 million (down 47.9% YoY), and the FY2026 annual result was $17.3 million, down 47.81% from the prior year.
• EBITDA climbed to $8.7 million in Q2 2026 per USNA's latest filing, from $799000.0 in the prior quarter.
• Over five years, EBITDA peaked at $34.7 million in Q1 2022 and troughed at -$6.6 million in Q3 2025.
• A 5-year average of $11.8 million and a median of $10.2 million in 2022 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2025: EBITDA surged 118.86% in 2023, then tumbled 137.91% in 2025.
• A 5-year view of EBITDA shows it stood at $20.0 million in 2022, then gained by 16.43% to $23.3 million in 2023, then slumped by 119.39% to -$4.5 million in 2024, then tumbled by 46.16% to -$6.6 million in 2025, then jumped by 231.79% to $8.7 million in 2026.
• Business Quant data shows USNA's EBITDA at $8.7 million in Q2 2026, $799000.0 in Q1 2026, and -$6.6 million in Q3 2025.